A5026274902- HIV Research and Treatment
- Virus-based gene therapy research
- Hepatitis B Virus Studies
- Viral gastroenteritis research and epidemiology
- RNA Interference and Gene Delivery
- Animal Virus Infections Studies
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- Bacteriophages and microbial interactions
- Acute Myeloid Leukemia Research
- Liver Disease Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Herpesvirus Infections and Treatments
- Virology and Viral Diseases
- Organ Transplantation Techniques and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Immune responses and vaccinations
- Veterinary Oncology Research
- HIV/AIDS drug development and treatment
- Immunodeficiency and Autoimmune Disorders
- T-cell and Retrovirus Studies
- Liver Diseases and Immunity
- Cytomegalovirus and herpesvirus research
- Glutathione Transferases and Polymorphisms
- Acute Lymphoblastic Leukemia research
Biocure (United States)
2016
North Shore University Hospital
2003
University of Pittsburgh
1995-1998
University of Florida
1993-1996
Florida College
1993
INTEGRIS Baptist Medical Center
1993
University of Tennessee at Knoxville
1988-1992
Abstract: The presence of bcl‐2 in myeloid leukemias has been associated with a decrease therapy‐induced apoptosis, reduced patient survival and vitro autonomous growth leukemic cells. present study focuses on the quantitation resistance to increasing doses 1‐β‐d‐arabinofuranosylcytosine (Ara‐C) by using hematological tumors expressing different levels bcl‐2. Scanning densitometry Western blots demonstrated that U‐937 cells express low (RD=0.008), whereas follicular lymphoma RL‐7 expressed...
In this study, we employ antisense RNA technology to block Hepatitis B Virus (HBV) gene expression in cell culture by transfer as an approach immune recognition and pathogenic sequelae. Retroviral vectors encoding sense copies of the HBV surface antigen (HBsAg) were constructed, respectively. To assay inhibition RNA, retroviral construct was co-transfected with vector (pTHBV) hepatoma line, HepG2 cells. Expression assessed a standard HBsAg assay. The results indicated that reduced (40-50%)...
Live attenuated vaccines prepared from simian immunodeficiency virus (SIV) have provided the best protective immunity in challenge experiments. In animals vaccinated with SIV, immune responses may be elicited owing to endogenous expression of native SIV proteins and/or antigen presentation replication site virus. However, replication-competent viral raise safety concerns for clinical trials humans. To ensure and maintain immunogenicity a live, vaccine, we developed replication-defective HIV...
Abstract It has been demonstrated that human immunodeficiency virus (HIV) replication can be effectively blocked by an antisense sequence was introduced into the lymphoid cell line through retroviral‐mediated gene transfer. In this study, it is RNA also inhibit simian (SIV) in peripheral blood mononuclear cells (MNCs) of healthy donors. MNCs were transduced with amphotropic recombinant encoding either sense or constructs SIV DNA fragments. After challenge SIV, viral suppressed...
Antisense RNA-mediated inhibition of HIV showed mixed success in previous experiments. In order to elucidate the parameters influencing efficacy an antisense RNA approach, retroviral vectors encoding 4.5 kb, 3.5 or 2.5 kb gag-pol region SIV (simian immunodeficiency virus) were constructed and used transduce a CD4-positive CEM174 cell line. The growth rate transduced cells was measured, results that RNAs have no detrimental effect on growth. Similar levels expression observed all by Northern...
Methods A010 is an ongoing randomized, placebo-controlled dose-escalation clinical trial to evaluate the safety and immunogenicity of two doses a replication defective HIV-1 vaccine (HIVAXTM) in subjects receiving stable highly active antiretroviral therapy (HAART) who have RNA 500 cells/mm3. Following randomized vaccination phase received meet eligibility will undergo 12-week analytical treatment interruption.
Background Live attenuated simian immunodeficiency virus (SIV) elicited the best protective immunity in rhesus monkeys. However, this vaccine approach was hindered by safety concerns that live HIV-1 may cause harms humans. To overcome problem, we have developed a replication defective HIV/SIV pseudotyped with Vesicular Stomatitis Virus G protein (VSV-G) as an AIDS model.